Evidence map›Paper›PMID 26783291›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2016

Exploring Issues of Comorbid Conditions in People Who Smoke.

Alana M Rojewski, Stephen Baldassarri, Nina A Cooperman, Ellen R Gritz, Frank T Leone, Megan E Piper, Benjamin A Toll, Graham W Warren, Comorbidities Workgroup of the Society for Research on Nicotine and Tobacco (SRNT) Treatment Network

Open access · bronzeAbstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Racial/ethnic discrimination and racial trauma: Concurrent evaluation among Black adults who smoke in the United States.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Impact of tobacco smoking on disease-specific outcomes in common neurological disorders: A scoping review.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Alana M RojewskiDepartment of Psychiatry, Yale School of Medicine, New Haven, CT; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC;
Stephen BaldassarriDepartment of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT;
Nina A CoopermanDepartment of Psychiatry, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;
Ellen R GritzDepartment of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX;
Frank T LeonePulmonary, Allergy, and Critical Care Division, University of Pennsylvania Presbyterian Medical Center, Philadelphia, PA;
Megan E PiperCenter for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin, Madison, WI;
Benjamin A TollDepartment of Psychiatry, Yale School of Medicine, New Haven, CT; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC; Department of Cancer Prevention and Control, Yale Cancer Center, New Haven, CT; Tobacco Treatment Service, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT; Tobacco Treatment and Lung Cancer Screening Programs, Hollings Cancer Center, Charleston, SC.
Graham W WarrenDepartment of Radiation Oncology, Medical University of South Carolina, Charleston, SC; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC warrengw@musc.edu.
Comorbidities Workgroup of the Society for Research on Nicotine and Tobacco (SRNT) Treatment Network
Medical University of South Carolina · USYale University · USJohnson University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Wisconsin–Madison · USUPMC Presbyterian · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Testing Relapse Recovery Intervention ComponentsP01CA180945 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI FIORE, MICHAEL C · 2014 to 2023
$23.0M
Transforming The Treatment of Tobacco Use in Health Care: Seizing The Potential of the Electronic Health Record to Deliver Comprehensive Chronic Care Treatment for SmokingR35CA197573 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MICHAEL C FIORE · 2015 to 2026
$10.7M
Research Training Fellowship in Substance use and Addiction (RTFSA)T32DA007238 · NIDA · YALE UNIVERSITY · PI BRIAN D. KILUK, ISMENE L. PETRAKIS · 1988 to 2026
$5.7M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA180945NCI NIH HHS R35 CA197573NIDA NIH HHS T32 DA007238
6 · The paper itself

Abstract

unlabelledSmoking affects comorbid disease outcomes, and patients with comorbid conditions may have unique characteristics that are important to consider when treating tobacco use. However, addressing tobacco in patients being treated for comorbid conditions is not a consistent practice. Recognizing the need for a "call-to-action" to address tobacco use in people with comorbid conditions, the Tobacco Treatment Network within the Society for Research on Nicotine and Tobacco (SRNT) convened a Comorbidities Workgroup to explore the relationship between smoking and comorbid disease to identify common themes including: the harms associated with continued tobacco use, the frequency of comorbid disease and tobacco use, the potential effect of comorbid disease on the ability to quit tobacco use, the association between tobacco use and suboptimal disease-specific treatment response, and evidence regarding potential approaches to improve addressing tobacco use in patients with comorbid disease. Five candidate conditions (psychiatric, cancer, cardiovascular, pulmonary, and human immunodeficiency virus infected patients) were explored. Across comorbid conditions, smoking adversely affects treatment efficacy and promotes other adverse health conditions. People with comorbid conditions who smoke are motivated to quit and respond to evidence-based smoking cessation treatments. However, tobacco cessation is not regularly incorporated into the clinical care of many individuals with comorbidities. Optimal strategies for addressing tobacco use within each comorbid disease are also not well defined. Further work is needed to disseminate evidence-based care into clinical practice for smokers with comorbid disease and addiction research should consider comorbid conditions as an important construct to explore. IMPLICATIONS: This article explores how physical and psychiatric conditions may interact in the treatment of tobacco dependence, and discusses the need for smoking cessation as a critical component of comorbid condition management. Five common comorbid domains-psychiatric, cancer, pulmonary, cardiovascular, and human immunodeficiency virus (HIV)-are highlighted to illustrate how these different conditions might interact with smoking with respect to prevalence and harm, motivation to quit, and cessation treatment utilization and success.

Indexed as

SmokingComorbidityHumansSmoking Cessation

Identifiers

PMID26783291
PMCPMC4941598
OpenAlexW2286182952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.